Aperio Group LLC lifted its stake in Haemonetics Co. (NYSE:HAE) by 47.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,446 shares of the medical instruments supplier’s stock after acquiring an additional 5,579 shares during the quarter. Aperio Group LLC’s holdings in Haemonetics were worth $1,999,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in the company. UBS Group AG increased its position in shares of Haemonetics by 17.9% during the 1st quarter. UBS Group AG now owns 14,396 shares of the medical instruments supplier’s stock valued at $1,053,000 after purchasing an additional 2,185 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Haemonetics by 3.7% in the 1st quarter. Principal Financial Group Inc. now owns 446,448 shares of the medical instruments supplier’s stock worth $32,662,000 after acquiring an additional 16,073 shares during the last quarter. Allianz Asset Management GmbH acquired a new position in shares of Haemonetics in the 1st quarter worth $8,313,000. Bank of Montreal Can grew its holdings in shares of Haemonetics by 195.7% in the 2nd quarter. Bank of Montreal Can now owns 4,172 shares of the medical instruments supplier’s stock worth $375,000 after acquiring an additional 2,761 shares during the last quarter. Finally, Fox Run Management L.L.C. grew its holdings in shares of Haemonetics by 45.5% in the 2nd quarter. Fox Run Management L.L.C. now owns 4,573 shares of the medical instruments supplier’s stock worth $410,000 after acquiring an additional 1,431 shares during the last quarter. Hedge funds and other institutional investors own 96.44% of the company’s stock.
In other news, Director Pedro P. Granadillo sold 30,824 shares of Haemonetics stock in a transaction on Monday, September 17th. The stock was sold at an average price of $111.83, for a total transaction of $3,447,047.92. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jacqueline Scanlan sold 4,890 shares of Haemonetics stock in a transaction on Monday, September 10th. The shares were sold at an average price of $112.19, for a total value of $548,609.10. The disclosure for this sale can be found here. Insiders have sold 62,653 shares of company stock worth $6,973,391 in the last quarter. 1.04% of the stock is currently owned by corporate insiders.
Shares of NYSE HAE opened at $111.61 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.94 and a current ratio of 2.92. The firm has a market capitalization of $5.62 billion, a P/E ratio of 59.68, a P/E/G ratio of 3.52 and a beta of 1.09. Haemonetics Co. has a 52-week low of $53.74 and a 52-week high of $117.56.
Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.02. The business had revenue of $241.58 million for the quarter, compared to analysts’ expectations of $233.44 million. Haemonetics had a return on equity of 16.04% and a net margin of 2.26%. The company’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 EPS. As a group, research analysts expect that Haemonetics Co. will post 2.32 EPS for the current fiscal year.
A number of equities analysts recently issued reports on the company. Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 7th. Morgan Stanley lifted their target price on Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, August 8th. Barrington Research lifted their target price on Haemonetics from $90.00 to $118.00 and gave the stock an “outperform” rating in a report on Thursday, August 9th. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 target price on the stock in a report on Friday, October 12th. Finally, TheStreet cut Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $113.20.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/haemonetics-co-hae-shares-bought-by-aperio-group-llc.html.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Story: What are the components of an earnings report?
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.